Zimmer Biomet Holdings (ZBH) Earnings Date & Reports

Key Takeaways

• Zimmer Biomet reported third-quarter 2026 net sales of $2.063 billion, up 3.1% on a reported basis and 3.7% in constant currency.
• Adjusted diluted earnings per share (EPS) came in at $1.90, roughly in line with the prior-year quarter and modestly above analyst consensus estimates.
• GAAP (Generally Accepted Accounting Principles) diluted EPS was $1.00, down from $1.16 a year earlier, reflecting higher selling and transformation-related costs.
• Hips, the S.E.T. franchise, and Technology & Data segments grew strongly, while the company's largest category, Knees, continued to decline.
• Management raised its full-year 2026 outlook for both organic constant-currency revenue growth and adjusted EPS.
• For more on this company, explore its Major News, Today's Price Move, Price Targets, and Forecast.
• Discover additional market opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Zimmer Biomet's third-quarter report offers investors a progress check on the company's multi-year effort to diversify beyond its core joint-replacement franchise into faster-growing areas such as robotics, data solutions, and extremities. Coming after several quarters of softness in the knee business, the results matter because they reveal whether that headwind is being offset by momentum elsewhere in the portfolio. The quarter also carried significance as management continued a U.S. sales-force transition designed to sharpen commercial execution, a restructuring that has created near-term disruption. With the company approaching its 100-year anniversary and relying on its Paragon 28 acquisition to accelerate foot-and-ankle growth, this earnings release was a key test of whether its diversification strategy can sustain consolidated growth.

Reported Results

Zimmer Biomet posted third-quarter 2026 net sales of $2.063 billion, a 3.1% increase on a reported basis and 3.7% on a constant-currency basis, exceeding the consensus revenue estimate of roughly $2.04 billion. GAAP diluted EPS was $1.00, down from $1.16 in the prior-year quarter, while adjusted diluted EPS was $1.90, flat year over year and slightly above analyst estimates.

Results were uneven across the portfolio. Hips sales rose 6.0% on a reported basis (7.0% in constant currency), and the S.E.T. category (Sports Medicine, Biologics, Foot and Ankle, Upper Extremities, Trauma, Craniomaxillofacial and Thoracic) grew 6.8% reported and 7.1% in constant currency. Technology & Data, Bone Cement and Surgical climbed 11.9% reported and 13.0% in constant currency. In contrast, Knees — the company's largest product category — declined 3.1% on a reported basis and 2.6% in constant currency, weighed down by the U.S. sales-force transition and competitive and China-related pressures.

The company generated $560.0 million in operating cash flow and $372.4 million in free cash flow, both up roughly 34% year over year. Management also raised full-year 2026 guidance, lifting organic constant-currency sales growth to a range of 3.0% to 3.5% and adjusted EPS to a range of $8.50 to $8.60.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names such as Zimmer Biomet, the AI Screener can be a useful way to compare peers and monitor shifting momentum across the medical-device sector.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was cautious, reflecting persistent concerns about knee weakness and the disruptive U.S. sales-force transition. The top-line beat and the upward revision to full-year guidance provided a positive offset, while the decline in GAAP earnings and the year-over-year dip in adjusted operating margin underscored the cost of the commercial restructuring. Early trading showed a modestly negative move in the shares, suggesting investors were weighing the encouraging diversification momentum against ongoing knee headwinds and elevated spending. Overall, the results reinforced the view that Zimmer Biomet's growth is becoming broader-based even as its largest franchise continues to lag.

Forward Outlook and Key Factors to Monitor

Management's raised guidance signals growing confidence in the diversification strategy, but several items will shape the narrative in coming quarters. First, investors should watch the U.S. sales-force transition, which is now roughly three-quarters complete. Management indicated the disruption is running ahead of schedule and less severe than initially expected, yet knees remain under pressure and are not expected to stabilize until the transition matures.

Second, the robotics and enabling-technology pipeline is a key catalyst. Zimmer Biomet expects to file a 510(k) application for its Monogram robotic system soon — significantly ahead of schedule — and now anticipates launching a fully autonomous version in the first half of 2027. Progress on hiring robotics sales specialists and the continued rollout of the Z1 hip stem and OrthoGrid platforms will be closely monitored.

Finally, margin and cost trends remain important. The company cited a roughly 46% operating-expense-to-sales ratio and is consolidating manufacturing facilities in Warsaw, Indiana, while shifting international production toward lower-cost locations. How quickly these efficiency initiatives translate into operating-margin improvement will be central to the stock's next leg. China-related headwinds are also expected to anniversary in early 2027, potentially easing pressure on international knees.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations